knowledge -WSS

knowledge

author：comprehensive 2025-09-30 23:40:27 - browse：9239

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Travis Kelce and the trap of celebrity vaccine endorsements

knowledge

WSS

NIH study of ME/CFS points to clear biological hallmarks

Medicare must police algorithms in Medicare Advantage, Dems say

Ed Silverman on new gene therapies, biosimilars, coffee, and more

STAT readers on older presidents, polypills, Medicare, and more

Coloradans with cystic fibrosis could lose access to Trikafta

A solution to the after

focus

knowledge

Wikipedia

In Memoriam: Notable people who died in 2023

Coloradans with cystic fibrosis could lose access to Trikafta

Novavax promises a turnaround & Lilly roils the obesity market

Medicare must police algorithms in Medicare Advantage, Dems say

What does generative AI mean for health care? We asked experts

A new nitrogen execution bill also undermines medical licensing

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Alabama IVF ruling threatens families facing fatal genetic disease

At least 13 dead in Texas as scorching temps continue

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Wikipedia

Key Senate panel to consider PBM, drug pricing reform package

DeepMind touts AlphaFold's new skills as protein folding AI models face off

STAT readers on older presidents, polypills, Medicare, and more

Alabama hospital puts IVF treatments on hold

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

focus

focus

knowledge

hotspot